tiprankstipranks
Veritas In Silico Partners with MGC for RNA Drug Development
Company Announcements

Veritas In Silico Partners with MGC for RNA Drug Development

Veritas In Silico Inc. (JP:130A) has released an update.

Don't Miss our Black Friday Offers:

Veritas In Silico Inc. (VIS) has signed a memorandum of understanding with Mitsubishi Gas Chemical (MGC) to jointly research, develop, and manufacture innovative RNA-targeted drugs. Utilizing VIS’s ibVIS® discovery platform and MGC’s expertise in GMP manufacturing, the partnership aims to create high-quality nucleic acid medicines. This collaboration, however, is not expected to affect VIS’s financial forecasts for the fiscal year ending December 2024.

For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App